German China India

France: Pharmaceutical Industry

Advent Close to Acquiring Sanofi's European Generics Division

| Editor: Alexander Stark

Advent is said to near deal to acquire Sanofi Generics Unit
Gallery: 1 image
Advent is said to near deal to acquire Sanofi Generics Unit (Source: Bloomberg Finance LP)

Advent International is apparently close to acquiring Sanofi’s European generics division in a deal valued at about $ 2.5 billion including debt.

Paris/France (Bloomberg) — The French drugmaker’s board is scheduled to meet as early as Monday (April 16) to sign off on the deal, which could be announced in coming days, the people who have knowledge of the matter said, asking not to be identified because the deliberations are private. No final decision has been made and the talks may still fall apart, they said.

Representatives for Sanofi couldn’t immediately be reached for comment. A spokesman for Advent declined to comment.

An accord would signal the culmination of a process that began more than two years ago as Chief Executive Officer Olivier Brandicourt started to shift the drugmaker’s focus to biotechnology and new medicines. The sale would add to the more than $ 15 billion in transactions that Sanofi has announced so far this year, including the acquisition of Bioverativ Inc. to expand in hemophilia treatments and Ablynx NV to gain an experimental medicine for another rare bleeding disorder.

Advent and BC Partners were going head to head in competing to buy the generics business known as Zentiva, people familiar with the matter had said Friday. Other final bidders in the process included Brazilian drugmaker EMS and buyout firm Carlyle Group LP, they said.

Zentiva, based in Prague, focuses on developing, manufacturing and marketing generic pharmaceutical products and traces its roots back to the Black Eagle pharmacy in the 15th century, according to its website. Sanofi acquired the business in 2009, three years after becoming its largest shareholder.

Torrent Pharmaceuticals Acquires US-based Bio-Pharm

Pharma Acquisition

Torrent Pharmaceuticals Acquires US-based Bio-Pharm

01/22/2018 - With this move, Torrent Pharmaceuticals has established its presence in the USA. The acquisition will also enable the company to growth further in the field of manufacturing and R&D. read...

The French drugmaker separately is selling twelve pharmaceutical brands to Charterhouse Capital Partners LLP’s portfolio company Cooper-Vemedia for € 158 million ($ 195 million), according to a statement. The products are split across dermatology, well-being, eye care and other fields.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45251326 / Pharma & Food)